Literature DB >> 10328588

New chemotherapy options for the treatment of malignant gliomas.

E Burton1, M Prados.   

Abstract

Chemotherapy remains part of the treatment triad that includes surgery and radiation therapy for the management of malignant gliomas. In recent years there has been an increased understanding of the molecular pathways of malignant transformation. Based on this research, new drugs have been evaluated, with specific cellular targets in mind that can be modified or inhibited. Many of these agents are now being tested in phase I and II clinical trials and have shown some promising results. Clearly, not all patients with malignant gliomas respond equally to chemotherapy. Recent evidence suggests that certain molecular markers may predict chemosensitivity in some tumor types, particularly anaplastic oligodendroglioma. This article reviews recent trends in the use of chemotherapy and clinical trials of new therapies for adults with malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10328588     DOI: 10.1097/00001622-199905000-00003

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  14 in total

1.  Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme.

Authors:  M A Rosenthal; M L Gruber; J Glass; A Nirenberg; J Finlay; H Hochster; F M Muggia
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

2.  High concentration of Daunorubicin and Daunorubicinol in human malignant astrocytomas after systemic administration of liposomal Daunorubicin.

Authors:  K W Albrecht; P C de Witt Hamer; S Leenstra; P J Bakker; J H Beijnen; D Troost; P Kaaijk; A D Bosch
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

Review 3.  Gene therapy and targeted toxins for glioma.

Authors:  Maria G Castro; Marianela Candolfi; Kurt Kroeger; Gwendalyn D King; James F Curtin; Kader Yagiz; Yohei Mineharu; Hikmat Assi; Mia Wibowo; A K M Ghulam Muhammad; David Foulad; Mariana Puntel; Pedro R Lowenstein
Journal:  Curr Gene Ther       Date:  2011-06       Impact factor: 4.391

Review 4.  Gene therapy and targeted toxins for glioma.

Authors:  Gwendalyn D King; James F Curtin; Marianela Candolfi; Kurt Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

Review 5.  Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.

Authors:  J Andrew Skirvin; Stuart M Lichtman
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 6.  Pharmacotherapy of malignant astrocytomas of children and adults: current strategies and future trends.

Authors:  M T Jennings; S Iyengar
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

7.  Temozolomide as first-line agent in treating high-grade gliomas: phase II study.

Authors:  S Chibbaro; L Benvenuti; A Caprio; S Carnesecchi; F Pulerà; F Faggionato; D Serino; C Galli; M Andreuccetti; N Buxton; R Gagliardi
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

8.  Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.

Authors:  Susan L Chua; Mark A Rosenthal; Shirley S Wong; David M Ashley; Anne-Marie Woods; Anthony Dowling; Lawrence M Cher
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

9.  Intracranial stereotaxic cannulation for development of orthotopic glioblastoma allograft in Sprague-Dawley rats and histoimmunopathological characterization of the brain tumor.

Authors:  Surajit Karmakar; M Foster Olive; Naren L Banik; Swapan K Ray
Journal:  Neurochem Res       Date:  2007-08-15       Impact factor: 3.996

Review 10.  Recurrent malignant glioma in adults.

Authors:  Stephen B Tatter
Journal:  Curr Treat Options Oncol       Date:  2002-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.